Covid-19 delays short term revenue, while the commercial launch of IRRAflow and Hummingbird progresses
· Normal business operations and short-term revenue impacted by covid-19 pandemic and associated restrictions · In spite of covid-19 challenges, forward progress shown with global commercial product launches · First European patients treated with IRRAflow after CE Mark recertification · IRRAflow capital systems also placed in additional EU marketsStockholm, June 30, 2020 – IRRAS AB, a commercial stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today provided an update on the launch of its IRRAflow® and Hummingbird ICP